Study Summary
This is a single-arm open-label phase I study to determine the effect of CD19- CAR-T Cells infusion followed by allogeneic stem cell transplantation in safety, efficacy and engraftment potential in patients with CD19+ B-lineage leukemia and lymphoma.
Want to learn more about this trial?
Request More InfoInterventions
anti-CD19 CAR-TBIOLOGICAL
Ex vivo-expanded autologous T cells modified to express CD19 CAR
FludarabineDRUG
Patients were given cyclophosphamide 500mg/m2/day on day -4 and fludarabine at 25 mg/m2/day on day -4, day -3, and day -2.
CyclophosphamideDRUG
Patients were given cyclophosphamide 500mg/m2/day on day -4.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| The First Affilicated Hospital of Wenzhou Medical University | Wenzhou | Zhejiang | China |